Synthesis and structure activity relationships of glycine amide derivatives as novel Vascular Adhesion Protein-1 inhibitors.

  title={Synthesis and structure activity relationships of glycine amide derivatives as novel Vascular Adhesion Protein-1 inhibitors.},
  author={Susumu Yamaki and Daisuke Suzuki and Jiro Fujiyasu and Masahiro Neya and Akira Nagashima and Mitsuhiro Kondo and Takafumi Akabane and Keitaro Kadono and Ayako Moritomo and Kosei Yoshihara},
  journal={Bioorganic \& medicinal chemistry},
  volume={25 1},

Figures and Tables from this paper

Human Copper-Containing Amine Oxidases in Drug Design and Development
The choice of the model organism for preclinical testing of hVAP-1 inhibitors is not either trivial due to species-specific binding properties of designed inhibitors and different repertoire of copper-containing amine oxidase family members in mammalian species, and the facts that should be considered are discussed in light of the applied structural bioinformatics and structural biology approaches.
ω‐(5‐Phenyl‐2H‐tetrazol‐2‐yl)alkyl‐substituted hydrazides and related compounds as inhibitors of amine oxidase copper containing 3 (AOC3)
To obtain novel inhibitors of the enzyme, the amino group of this substrate was replaced with functional groups that occur in known AOC3 inhibitors, such as hydrazide or glycine amide moieties, and derivatives of the compounds obtained in this way were prepared.
pH‐permeability profiles for drug substances: Experimental detection, comparison with human intestinal absorption and modelling
  • M. OjaU. Maran
  • Biology
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2018
HPLC–UV assay for the evaluation of inhibitors of plasma amine oxidase using crude bovine plasma
Investigation of whether crude bovine plasma can be used as enzyme source in this assay instead of the purified enzyme, and inhibition data of the known PAO inhibitor 2-amino-N-(3-phenylbenzyl)acetamide and a newly synthesised meta-substituted derivative of 16 reflect the two-step inhibition mechanism of these covalent inhibitors.


Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey
This paper reviews the patent literature of SSAO/VAP-1 inhibitors and substrates, for the period of 1990 – 2010, along with their chemical structures and pharmacological uses.
Vascular adhesion protein-1: Role in human pathology and application as a biomarker
The general characteristics and biological functions of V AP-1 are reviewed, focusing on its important role as a prognostic biomarker in human pathologies and the potential therapeutic application of VAP-1 inhibitors will be discussed.
Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1.
The structure of an adduct of SSAO and the irreversible inhibitor 2-hydrazinopyridine has been solved and refined to 2.9 A resolution and will aid efforts to identify natural substrates, provide valuable information for the design of specific inhibitors and direct further studies.
Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner
Diabetic and obese animals have increased plasma SSAO activity associated with VAP-1 protein, and 3T3-L1 adipocytes and human adipose tissue explants release a soluble form of V AP-1/SSAO, which derives from the membrane.
Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo.
These are the first data to demonstrate that the enzymatic activity of the atypical endothelial adhesion molecule AOC3, and possibly that of other closely related ecto-oxidases, is crucial for leukocyte exit from the vessels in inflamed joints in vivo.
Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration
Results highlight the potential of inhibiting of VAP-1/SSAO enzymatic function, by PXS-4728A, as a novel therapeutic approach in lung diseases that are characterized by neutrophilic pattern of inflammation.